Economic analysis of the use of drugs for the treatment of hemophilia A, B and Willebrand's disease
Relevance. Therapy of hemophilia A, B and Willebrand's disease is carried out under the program of 14 VZN due to the use of federal budget funds. The use of funding is increasing in line with the growth of the total number of patients. In 2022,85.99 billion rubles were allocated, which correspo...
Saved in:
Main Authors: | D. S. Fokina (Author), O. V. Zhukova (Author), A. L. Khokhlov (Author), S. A. Volkova (Author) |
---|---|
Format: | Book |
Published: |
Izdatelstvo OKI,
2024-02-01T00:00:00Z.
|
Subjects: | |
Online Access: | Connect to this object online. |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Quality of life of patients with different forms of hemophilia on the example of Nizhny Novgorod region
by: D. S. Fokina, et al.
Published: (2024) -
Human von Willebrand factor/factor VIII concentrates in the management of pediatric patients with von Willebrand disease/hemophilia A
by: Castaman G, et al.
Published: (2016) -
Analysis of the long-term effectiveness of a drug in the treatment of a chronic disease is the basis of rational pharmacotherapy (on the example of the use of roflumilast in the treatment of chronic obstructive pulmonary disease)
by: O. V. Zhukova, et al.
Published: (2020) -
Managing Pregnant Women with Hemophilia and von Willebrand Disease: How Do We Provide Optimum Care and Prevent Complications?
by: Janbain M, et al.
Published: (2022) -
COMPARATIVE ANALYSIS OF DRUG EFFICACY IN THE TREATMENT FOR COVID-19 SEVERE FORMS, BASED ON ATTRIBUTE-BASED STATISTIC METHODS AND ANALYSIS OF DRUG INTERACTIONS
by: O. V. Zhukova, et al.
Published: (2021)